Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $12,835.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd F. Petersen sold 500 shares of the company's stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $25.67, for a total transaction of $12,835.00. Following the completion of the transaction, the director now owns 72,909 shares in the company, valued at approximately $1,871,574.03. This represents a 0.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Amphastar Pharmaceuticals Stock Up 1.8%

Shares of AMPH traded up $0.47 during mid-day trading on Friday, hitting $25.99. 359,174 shares of the company's stock were exchanged, compared to its average volume of 486,174. The firm has a fifty day moving average of $24.64 and a two-hundred day moving average of $31.42. Amphastar Pharmaceuticals, Inc. has a twelve month low of $22.64 and a twelve month high of $53.96. The stock has a market cap of $1.23 billion, a price-to-earnings ratio of 8.66, a P/E/G ratio of 2.19 and a beta of 0.77. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Wall Street Analyst Weigh In

Several research analysts have weighed in on AMPH shares. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Thursday, April 10th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 price objective (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a research note on Monday, May 12th. Piper Sandler dropped their price objective on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Finally, Wells Fargo & Company dropped their price objective on shares of Amphastar Pharmaceuticals from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, May 8th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to MarketBeat, Amphastar Pharmaceuticals has an average rating of "Hold" and a consensus target price of $32.33.

Institutional Trading of Amphastar Pharmaceuticals

Several large investors have recently modified their holdings of the company. TD Asset Management Inc boosted its holdings in shares of Amphastar Pharmaceuticals by 20.2% during the 1st quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after buying an additional 371,856 shares during the period. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 11.5% during the 1st quarter. Fuller & Thaler Asset Management Inc. now owns 1,263,598 shares of the company's stock worth $36,632,000 after buying an additional 130,672 shares during the period. Epoch Investment Partners Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 14.5% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company's stock worth $36,565,000 after buying an additional 160,034 shares during the period. Boston Trust Walden Corp boosted its holdings in shares of Amphastar Pharmaceuticals by 24.2% during the 1st quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock worth $35,241,000 after buying an additional 236,704 shares during the period. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of Amphastar Pharmaceuticals by 9.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,198,590 shares of the company's stock worth $44,503,000 after buying an additional 105,288 shares during the period. 65.09% of the stock is owned by institutional investors.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.